Cypher Shines At Taxus’ Expense: J&J Captures 46% Of U.S. Market
Johnson & Johnson/Cordis plans to increase its manufacturing capacity to be able to supply three-quarters of the U.S. drug-eluting stent market with Cypher by June 2006
Johnson & Johnson/Cordis plans to increase its manufacturing capacity to be able to supply three-quarters of the U.S. drug-eluting stent market with Cypher by June 2006